Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $67.10
    -1.90 (-2.75%)

    Market Cap: $16.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Exelixis Inc (EXEL) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Exelixis (EXEL) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Exelixis reported EPS of $0.85, above the $0.79 estimate. It beat the EPS estimate in each of the last 10 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    79%(31/39)
    Avg Surprise
    +58.12%
    Streak
    10 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.00
    Range$0.77 - $1.23
    19 analysts
    Revenue Consensus
    $672.09M
    Range$625.53M - $721.35M
    17 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.88
    Range$0.82 - $0.94
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.94-6.3%
    60d ago$0.97-9.3%
    30d ago$0.94-6.4%
    7d ago$0.94-6.4%
    Current$0.88
    Revenue Consensus
    $690.77M
    Range$670.00M - $722.13M
    4 analysts

    Next Report

    EXEL has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.4% above the $0.94 reported for the quarter ended Dec 31, 2025.

    EXEL Earnings Call

    The latest EXEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, EXEL beat 31, missed 4 and matched 4. The widest gap in the table came in the quarter ended Mar 31, 2017, when EPS landed 600.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.85$0.79N/A+7.59%Beat+9.0%101 up, 2 downOct 29, 2026N/A
    Jun 30, 2026$0.82$0.75N/A+9.33%Beat+9.3%112 up, 0 downAug 5, 2026$628.69M
    Mar 31, 2026$0.87$0.76$0.69 - $0.82+14.47%Beat+40.3%101 up, 2 downMay 5, 2026$610.81M
    Dec 31, 2025$0.94$0.81$0.38 - $1.02+16.05%Beat+70.9%136 up, 1 downFeb 10, 2026$598.66M
    Sep 30, 2025$0.78$0.67$0.53 - $0.71+16.42%Beat+66.0%131 up, 1 downNov 4, 2025$597.75M
    Jun 30, 2025$0.75$0.65$0.52 - $0.72+15.38%Beat-10.7%124 up, 1 downJul 28, 2025$568.26M
    Mar 31, 2025$0.62$0.37$0.34 - $0.55+69.12%Beat+264.7%113 up, 0 downMay 13, 2025$555.45M
    Dec 31, 2024$0.55$0.49$0.24 - $0.63+12.24%Beat+66.7%145 up, 2 downFeb 11, 2025$566.75M
    Sep 30, 2024$0.47$0.42N/A+11.90%Beat+370.0%134 up, 1 downOct 29, 2024$539.54M
    Jun 30, 2024$0.84$0.37N/A+127.03%Beat+171.0%155 up, 1 downAug 6, 2024$637.18M
    Mar 31, 2024$0.17$0.29$0.11 - $0.47-41.38%Miss+6.3%154 up, 1 downApr 30, 2024$425.23M
    Dec 31, 2023$0.33$0.31N/A+6.45%BeatN/A137 up, 3 downFeb 6, 2024$479.65M
    Sep 30, 2023$0.10$0.19-$0.13 - $0.27-47.37%Miss-67.7%130 up, 2 downNov 1, 2023$471.92M
    Jun 30, 2023$0.31$0.22$0.09 - $0.22+40.91%Beat+10.7%122 up, 1 downAug 1, 2023$469.85M
    Mar 31, 2023$0.16$0.22N/A-27.27%Miss-38.5%131 up, 0 downMay 9, 2023$408.79M
    Dec 31, 2022-$0.03-$0.05-$0.24 - $0.07+40.00%Beat-108.6%115 up, 0 downFeb 7, 2023$423.92M
    Sep 30, 2022$0.31$0.24$0.10 - $0.25+29.17%Beat+55.0%111 up, 3 downNov 1, 2022$411.74M
    Jun 30, 2022$0.28$0.24$0.10 - $0.24+16.67%Beat-24.3%101 up, 3 downAug 9, 2022$419.43M
    Mar 31, 2022$0.26$0.23N/A+13.04%Beat+188.9%91 up, 0 downMay 10, 2022$355.98M
    Dec 31, 2021$0.35$0.16-$0.04 - $0.17+118.75%Beat+150.0%10N/AFeb 17, 2022$451.14M
    Sep 30, 2021$0.20$0.27N/A-25.93%Miss+400.0%10N/ANov 2, 2021$328.42M
    Jun 30, 2021$0.37$0.14N/A+164.29%Beat+48.0%12N/AAug 5, 2021$385.18M
    Mar 31, 2021$0.09$0.09N/A0.00%In line-52.6%12N/AMay 6, 2021$270.23M
    Dec 31, 2020$0.14$0.10-$0.05 - $0.12+40.00%Beat-36.4%11N/AFeb 10, 2021$270.05M
    Sep 30, 2020$0.04$0.04-$0.16 - $0.100.00%In line-88.2%12N/ANov 5, 2020$231.09M
    Jun 30, 2020$0.25$0.14$0.08 - $0.18+78.57%Beat-13.8%12N/AAug 6, 2020$259.48M
    Mar 31, 2020$0.19$0.17$0.03 - $0.21+11.76%Beat-20.8%11N/AMay 5, 2020$226.91M
    Dec 31, 2019$0.22$0.17$0.10 - $0.22+29.41%Beat-40.5%11N/AFeb 25, 2020$240.31M
    Sep 30, 2019$0.34$0.22N/A+54.55%Beat-17.1%9N/AOct 30, 2019$271.70M
    Jun 30, 2019$0.29$0.28N/A+3.57%Beat+3.6%11N/AJul 31, 2019$240.28M
    Mar 31, 2019$0.24$0.24$0.20 - $0.300.00%In line-35.1%11N/AMay 1, 2019$215.49M
    Dec 31, 2018$0.37$0.23$0.16 - $0.33+60.87%Beat+208.3%11N/AFeb 12, 2019$228.60M
    Sep 30, 2018$0.41$0.17$0.10 - $0.31+141.18%Beat+57.7%10N/ANov 1, 2018$225.40M
    Jun 30, 2018$0.28$0.16$0.11 - $0.24+75.00%Beat+250.0%8N/AAug 1, 2018$186.11M
    Mar 31, 2018$0.37$0.15$0.08 - $0.30+146.67%Beat+640.0%8N/AMay 2, 2018$213.72M
    Dec 31, 2017$0.12$0.12$0.08 - $0.170.00%In line0.0%10N/AFeb 26, 2018$120.07M
    Sep 30, 2017$0.26$0.07$0.05 - $0.11+271.43%Beat+2500.0%10N/ANov 1, 2017$152.51M
    Jun 30, 2017$0.08$0.03$0.01 - $0.07+166.67%BeatN/A9N/AAug 2, 2017$99.01M
    Mar 31, 2017$0.05-$0.01N/A+600.00%BeatN/AN/AN/AMay 1, 2017$80.89M
    Dec 31, 2016$0.12-$0.01N/AN/AN/AN/AN/AN/AFeb 27, 2017$77.58M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.09, up 52.2% from the year before. It was -$0.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.09+52.2%
    Dec 31, 2024$2.03+125.6%
    Dec 31, 2023$0.90+9.8%
    Dec 31, 2022$0.82-18.8%
    Dec 31, 2021$1.01+62.9%
    Dec 31, 2020$0.62-43.1%
    Dec 31, 2019$1.09-23.8%
    Dec 31, 2018$1.43+180.4%
    Dec 31, 2017$0.51N/A
    Dec 31, 2016-$0.30N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,100 words across 20 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,13820
    2026Q2Jun 30, 20266,86819
    2026Q1Mar 31, 20267,12618
    2025Q4Dec 31, 20258,54823
    2025Q3Sep 30, 20257,74619
    2025Q2Jun 30, 20258,19823
    2025Q1Mar 31, 20258,59122
    2024Q4Dec 31, 20246,02220

    2026Q3 Earnings Call

    Opening remarks

    Andrew Peters Senior Vice President of Strategy and Investor Relations Thank you, Towanda, and thank you all for joining us for the Exelixis Third Quarter 2026 Financial Results Conference Call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; Dana Aftab, our Executive Vice President of Research and Development; and P.J. Haley, our Executive Vice President of Commercial, who will review our progress for the third quarter of 2026, ended September 30, 2026. During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website, for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results. During the course of the presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters, potential growth opportunities, and government drug pricing policies and initiatives. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the Securities and Exchange Commission, which, under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities. With that, I'll turn the call over to Mike.

    Michael Morrissey President and CEO All right. Thank you, Andrew, and thanks to everyone for joining us on the call today. Exelixis had a strong third quarter and continues to advance the key components of our business. The company is well positioned to deliver on our strategic objectives and tactical goals for 2026 and beyond as we aspire to become a company with a diverse pipeline of potential oncology franchise assets and opportunities. Most importantly, zanzalintinib is positioned to drive the next phase of growth for Exelixis as our second franchise molecule, potentially first with the third-line-plus CRC opportunity, followed by several waves of pivotal trials that we'll highlight today. CABO's strong third quarter performance reinforces our confidence in its long-term revenue growth trajectory. We saw solid year-over-year growth in both the RCC and NET indications in Q3 and are excited about the potential of the CABO NET indication, which serves as the foundation of our future expanded NET franchise with zanza and other molecules in our pipeline.

    Frequently Asked Questions About EXEL

    When is Exelixis's next earnings date?

    Exelixis's next earnings report is expected for Feb 8, 2027.

    Did EXEL beat earnings estimates last quarter?

    Yes. Exelixis reported EPS of $0.85 for the quarter ended Sep 30, 2026, above the $0.79 estimate, a 7.59% surprise.

    What EPS do analysts expect from EXEL next quarter?

    The consensus EPS estimate for Exelixis for the quarter ending Dec 31, 2026 is $1.00 from 19 analysts, with estimates from $0.77 to $1.23.

    How often does EXEL beat earnings estimates?

    Exelixis beat the EPS estimate in each of the last 10 quarters, with an average surprise of +29.96%.